Acasti Pharma Inc

Grace Therapeutics, Inc., based in Princeton, NJ, is a late-stage biopharmaceutical company focused on developing innovative drug candidates for rare and orphan diseases, particularly in the realm of neurological disorders. The company aims to transform the treatment landscape for conditions such as aneurysmal subarachnoid hemorrhage (aSAH) through its lead clinical asset, GTx-104, which offers a breakthrough formulation of nimodipine for intravenous infusion. With a commitment to disrupting established standards of care, Grace Therapeutics has received Orphan Drug Designation from the FDA for its key assets and boasts a robust intellectual property portfolio. The company is currently enrolling patients in its pivotal Phase 3 safety trial, STRIVEON, to further evaluate the effectiveness of GTx-104 in improving patient outcomes and reducing healthcare costs. Generated from the website

Bristol-Myers Squibb Company is dedicated to the discovery, development and exploration of cancer fighting therapies that extend and enhance the lives of patients living with cancer. More than 40 years ago, Bristol-Myers Squibb built a unified vision for the future of cancer treatment. With experience, dedication and resolve, that vision led to the development of a diverse worldwide portfolio of anticancer therapies that are an important cornerstone of care today. Scientists at Bristol-Myers Squibb's Pharmaceutical Research Institute are studying ways to improve current cancer treatments and identify better, more effective medicines for the future. James M. Cornelius was elected chief executive officer of Bristol-Myers Squibb by the company s Board of Directors in April 2007, after serving as interim CEO since September 2006. Headquartered in New York, Bristol-Myers Squibb Company is a worldwide pharmaceutical and related health care-products company whose mission is to extend and enhance human life.

Soligenix, Inc. is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of allogeneic hematopoietic cell transplantation.